Show simple item record

dc.contributor.authorCox, H
dc.contributor.authorFord, N
dc.contributor.authorvon Schoen-Angerer, T
dc.date.accessioned2012-04-24T16:33:29Z
dc.date.available2012-04-24T16:33:29Z
dc.date.issued2012-03
dc.identifier.citationLancet 2012; 12:177en
dc.identifier.issn1474-4457
dc.identifier.pmid22361421
dc.identifier.doi10.1016/S1473-3099(12)70015-4
dc.identifier.urihttp://hdl.handle.net/10144/220334
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.thelancet.com/journals/laninf/article/PIIS1473-3099(12)70015-4/fulltexten
dc.rightsPublished by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/journals/laninf[/url] for further relevant comment.en
dc.subject.meshTuberculosisen
dc.subject.meshTuberculosis, Multidrug-Resistanten
dc.titleMoxifloxacin for tuberculosis - Authors' reply.en
dc.typeArticleen
dc.contributor.departmentMédecins Sans Frontières, Khayelitsha, Cape Town, South Africa; University of Cape Town, Cape Town, South Africa; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerlanden
dc.identifier.journalLancet Infectious Diseasesen
refterms.dateFOA2019-03-04T09:43:03Z


Files in this item

Thumbnail
Name:
1203_Cox_Moxifloxacin-for-tube ...
Size:
45.70Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record